Can biomarkers be used to improve patient selection and overall survival in patients starting immunotherapy treatment for non-small cell lung cancer (NSCLC) and genitourinary cancers

Not Applicable

Completed

• Conditions: Cancer - Lung - Non small cell; on-small cell lung cancer; Bladder cancer; Kidney Cancer; Non-small cell lung cancer; Cancer - Bladder; Cancer - Kidney

• Registration Number: ACTRN12620000090910
• Lead Sponsor: Ingham Institute for Applied Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-03
• Study Completion: 2021-11-25
• Last Update Posted: 24 January 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Histologically or cytologically confirmed non-small cell lung cancer, bladder cancer, kidney cancer
Must be commencing immunotherapy for NSCLC, renal or bladder cancer

Exclusion Criteria

Not commencing immunotherapy
No consent signed

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival - data-linkage to medical records [12 months after starting immunotherapy ];Progression Free Survival - data linkage to medical records [12 months after starting immunotherapy ];Response Rate - data linkage to medical records, progress CT scan [3 months after starting immunotherapy ]

Secondary Outcome Measures

Name	Time	Method
Adverse events (rash, enterocolitis, hyperthyroidism, hypothyroidism, hepatitis) - these will be evaluated by clinical examination, participant self-reported and data linkage to medical records [3 months, 6 months, 9 months and 12 months after starting immunotherapy ]